Why the first anti-obesity cannabis blocker failed and what researchers are trying instead
The CB1 receptor antagonist rimonabant was effective for obesity and smoking cessation but caused serious psychiatric side effects including depression and suicidal ideation, prompting new strategies like neutral antagonists and peripherally restricted drugs.
Quick Facts
What This Study Found
Rimonabant demonstrated effectiveness for treating obesity and smoking cessation but was withdrawn from the European market due to psychiatric side effects. Researchers are now pursuing neutral antagonists, peripherally restricted ligands, and allosteric modulators to avoid these risks.
Key Numbers
Rimonabant was the first-in-class CB1R antagonist. It was withdrawn from the European market after reports of anxiety, depression, and suicidal ideation.
How They Did This
Narrative review of two decades of research on CB1 receptor-targeted therapeutics, covering animal and human studies of various drug development strategies.
Why This Research Matters
The CB1 receptor remains one of the most promising drug targets for obesity and addiction, but the failure of rimonabant showed that blocking it in the brain carries serious mental health risks. New approaches could unlock the therapeutic potential without the danger.
The Bigger Picture
This story illustrates a broader challenge in cannabinoid medicine: the endocannabinoid system is deeply intertwined with mood regulation, so any drug targeting it must account for psychiatric consequences.
What This Study Doesn't Tell Us
This is a narrative review, not a systematic review. Some of the newer drug strategies discussed were still in preclinical stages at the time of writing.
Questions This Raises
- ?Can peripherally restricted CB1 antagonists deliver meaningful weight loss without crossing into the brain?
- ?Will allosteric modulators prove safe enough for long-term use?
Trust & Context
- Key Stat:
- Rimonabant withdrawn due to suicidal ideation risk
- Evidence Grade:
- Moderate: narrative review covering extensive preclinical and clinical evidence, though newer strategies lack human trial data.
- Study Age:
- Published in 2019.
- Original Title:
- Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
- Published In:
- Current topics in medicinal chemistry, 19(16), 1418-1435 (2019)
- Authors:
- Nguyen, Thuy(2), Thomas, Brian F(3), Zhang, Yanan(2)
- Database ID:
- RTHC-02204
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is rimonabant?
Rimonabant was a drug that blocked the CB1 cannabinoid receptor. It helped with weight loss and smoking cessation but caused serious psychiatric side effects and was pulled from the market.
What does "peripherally restricted" mean?
It means designing a drug that works on CB1 receptors in the body (gut, liver, fat tissue) but cannot cross into the brain, potentially avoiding the mood-related side effects.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-02204APA
Nguyen, Thuy; Thomas, Brian F; Zhang, Yanan. (2019). Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.. Current topics in medicinal chemistry, 19(16), 1418-1435. https://doi.org/10.2174/1568026619666190708164841
MLA
Nguyen, Thuy, et al. "Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.." Current topics in medicinal chemistry, 2019. https://doi.org/10.2174/1568026619666190708164841
RethinkTHC
RethinkTHC Research Database. "Overcoming the Psychiatric Side Effects of the Cannabinoid C..." RTHC-02204. Retrieved from https://rethinkthc.com/research/nguyen-2019-overcoming-the-psychiatric-side
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.